ISCOInternational Stem Cell Corp.

About International Stem Cell Corp. (ISCO)

International Stem Cell Corp. (ISCO) is a Biotechnology company headquartered in San Diego, CA, United States whose shares trade over-the-counter on the OTCQB tier.

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).

Products and services

International Stem Cell Corporation (ISCO) is a publicly traded biotechnology company with a powerful new stem cell technology called human parthenogenetic activation that promises to significantly advance the field of regenerative medicine.

ISCO key facts

Ticker symbol

ISCO

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

San Diego, CA, United States

Country of incorporation

US

Year of incorporation

2005

Employees

30

Estimated market cap

$888.5K (as of Apr 11, 2025)

Shares outstanding

8,004,389

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

International Stem Cell Corp. leadership

• Andrey Semechkin — CEO
• Russell A Kern — EVP, Chief Scientific Officer
• Investor Relations — IR

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with I